Taixi Therapeutics was co-founded by a retired distinguished professor from National Taiwan University along with graduates, focusing on the development of novel small molecule drugs. Taixi Therapeutics possesses a comprehensive drug design platform and drug design professionals with decades of rich experience. It also has chemical databases of various properties required for fine-tuning selectivity, providing for the development of various future indications and the optimization of tissue distribution, improving solubility as well as absorption and metabolic distribution, to rapidly produce highly druggable and promising new drugs. At the same time, Taixi Therapeutics also possesses an R&D team with rich experience in drug development. Through collaborative R&D by commissioning CRO or CMO companies, it implements efficient and precise project management mechanisms to achieve goals and reduce development risks.

Overall, Taixi is a biotech new drug development company without laboratory barriers, characterized as an asset-light, low-investment, and highly cost-effective company. Starting from novel biological theoretical foundations, it develops products with first-in-class/best-in-class potential value.

Therefore, it targets the selection of products with a value of over 1 billion USD. Firstly, it is committed to the exploration of HDAC inhibitors. Relying on past accumulated expertise and drug development experience, it focuses on the development of orphan drugs for unmet clinical needs to provide patients with high-quality therapeutic drugs.